Helen Hockings
Queen Mary University of London(GB)Cancer Research UK(GB)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Cancer Genomics and Diagnostics, Cancer Cells and Metastasis, Single-cell and spatial transcriptomics
Most-Cited Works
- → The role of MET in chemotherapy resistance(2021)105 cited
- → A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice(2019)61 cited
- → The role of PARP inhibitor combination therapy in ovarian cancer(2023)34 cited
- → Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancer(2023)16 cited
- → LiquidCNA: Tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations(2021)14 cited
- → Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control(2025)13 cited
- Is oestrogen neuroprotective?(2009)
- → A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer(2022)10 cited
- → Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer(2024)7 cited
- → Learning from Crisis: a Multicentre Study of Oncology Telemedicine Clinics Introduced During COVID-19(2021)6 cited